Date:2/2/2011

nt programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended Septembe
'/>"/>

SOURCE Inovio Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
2. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
3. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
4. Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives
5. Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.
6. Vanda Pharmaceuticals Files Shelf Registration Statement
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
9. Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government
10. JHP Pharmaceuticals and Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
11. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call